Neurotrope | Neurotrope to Present at the Biotech Showcase 2015 Conference
22552
post-template-default,single,single-post,postid-22552,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Neurotrope to Present at the Biotech Showcase 2015 Conference

 

Newark, NJ, January 6, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 – 14, 2015.

Charles S. Ramat, Chief Executive Officer of Neurotrope, will discuss the Company’s strategic initiatives. Also participating will be Chairman Paul E. Freiman and Chief Medical Officer Warren W. Wasiewski, M.D., F.A.A.P.

 

Details of the presentation are as follows:

 

Date: Wednesday, January 14, 2015

Time: 11:30 AM PT

Track: C – Mission II (4th Floor)

 

A live webcast may be accessed under the “Investors” tab on the Company’s website at https://neurotrope.com. The webcast will be archived for 90 days.

 

 

 

 

About Neurotrope

 

Neurotrope Bioscience Inc., the operating subsidiary of Neurotrope, Inc., was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) which are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe.  PKCe has been shown to play a central role in the regrowth or repair of nervous tissues, cells or cell products. Neurotrope’s pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer’s disease, and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer’s in patients. A Phase 2a study with bryostatin in the treatment of Alzheimer’s disease has completed patient dosing and as previously reported, release of the topline study results is expected early Q1. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms. Also, the Company, under its BRNI license, has the rights to develop the licensed technology for other cognitive dysfunctions, including orphan diseases, such as Fragile X Syndrome.

 

 

Forward-Looking Statements

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements include statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of commercially viable pharmaceuticals and diagnostics, and (ii) the timing or outcome of the Company’s Phase 2a study with bryostatin in the treatment of Alzheimer’s disease.  Such forward- looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and Quarterly Report on Form 10-Q for the fiscal nine months ended September 31, 2014. The Company does not undertake to update these forward-looking statements.

 

 

 

Please visit www.neurotropebioscience.com for further information.

 

For additional information, please contact:

Robert Weinstein
Chief Financial Officer
(914) 295-2765
rweinstein@neurotropebioscience.com